Compare Cigna Corp (CI) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs Marvell Technology Inc — how do they compare? Cigna Corp trades at $272.72 (market cap $73.56B), while Marvell Technology Inc trades at $216.22 (market cap $187.19B). The key difference: Marvell Technology Inc is far larger — about 2.5× Cigna Corp's market cap, and Cigna Corp pays the higher dividend (2.24%). Which is the better fit depends on your goals.
| CI | MRVL | |
|---|---|---|
Market Cap | $73.56B | $187.19B |
Sector | Health | Technology |
52-Week High | $311.00 | $316.43 |
52-Week Low | $244.41 | $62.31 |
Enterprise Value | $98.27B | $188.63B |
Dividend Yield | 2.24% | 0.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cigna (CI) trades at $282.49, up 2.63% with strong earnings beats in recent quarters. The stock shows bearish technical signals but benefits from low valuation ratios like a P/E of 11.68 and P/S of 0.27. Recent Q2 2026 results exceeded expectations, with EPS of $7.78 beating estimates, and the company raised its full-year guidance to at least $30.45 adjusted EPS, reflecting robust growth in health services and insurance segments.
The outlook is positive due to consistent earnings outperformance and raised guidance, though technical weakness and competitive pressures pose risks. Analyst consensus is strongly bullish with a $338.90 price target, indicating ~20% upside potential from current levels, supported by dividend payments and institutional accumulation.
MRVL trades at $218.72, up 3.89% today, with a bullish technical signal from moving averages but neutral oscillators. The stock has beaten EPS estimates for three consecutive quarters, with Q2 2026 expected at $0.928. Revenue grew to $5.77B in 2025, though net income was negative. Analyst consensus is strongly bullish with an 82% buy rating and a $275.68 price target, implying 26% upside. Recent news highlights AI infrastructure product launches and institutional buying interest.
Outlook is positive driven by AI growth and earnings momentum, but high valuation multiples (P/E 75.16) and geopolitical risks from U.S.-China trade tensions pose challenges. Cash flow trends show improvement, with 2026 net cash flow projected at $3.0B. Investors should weigh strong analyst support against margin pressures and competitive threats in the semiconductor sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
